Competitor Analysis: Anti-Infective Peptides
Competitor Analysis: Anti-Infective Peptides
The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Anti-Bacterial Peptides
Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram-positive and gram-negative infections, prevention of catheter-related infections, otitis media, gingivitis and many more.
Anti-Fungal Peptides
Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more.
Anti-Viral Peptides
Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).
The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Anti-Infective Peptides used to treat bacterial, viral and fungal infections provides a competitor evaluation in the field of R&D projects with anti-infective peptides as of October 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Anti-Bacterial Peptides
Anti-bacterial peptides are used to treat infectious diseases such as complicated skin and skin structure infections (cSSSI), gram-positive and gram-negative infections, prevention of catheter-related infections, otitis media, gingivitis and many more.
Anti-Fungal Peptides
Anti-fungal peptides are used to treat infections such as oesophageal candidiasis, aspergillosis, oral candida infections, vaginal yeast infections and many more.
Anti-Viral Peptides
Anti-viral peptides are used to treat infections such as HIV and AIDS, influenza incl. H5N1 strains, hepatitis C virus infections (HCV).
The report includes a compilation of current active projects in research and development of anti-infective peptides. In addition, the report lists company-specific R&D pipelines of anti-infective peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
2013 Sales of Major Anti-Infective Peptides
Anti-Bacterial Peptides
Anti-Fungal Peptides
Anti-Viral Peptides
Corporate Anti-Infective Peptide R&D Pipelines
Anti-Bacterial Peptides
Anti-Fungal Peptides
Anti-Viral Peptides
Corporate Anti-Infective Peptide R&D Pipelines
